StockData
LeonaBio, Inc. logo

LeonaBio, Inc. (LONA) stock

LONANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$2.65−0.11 (-3.99%)

Close on Nov 18, 2026Market cap $24.97MP/E –Yield –

LeonaBio r&d expenses

Research and development expenses are spending on new products and technology.

LeonaBio's R&D Expenses for the twelve months ending Jun 30, 2026 was $33.50M, down 5.0% year over year. For fiscal 2025 it was $17.50M, down 75.2% from the year before. The highest annual figure on record is $93.79M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.50M-75.2%
FY2024Dec 31, 2024$70.68M-24.6%
FY2023Dec 31, 2023$93.79M+52.6%
FY2022Dec 31, 2022$61.46M+43.6%
FY2021Dec 31, 2021$42.79M+222.1%
FY2020Dec 31, 2020$13.29M+250.3%
FY2019Dec 31, 2019$3.79M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.70M+247.0%
Q1 FY2026Mar 31, 2026$11.26M+161.8%
Q4 FY2025Dec 31, 2025$6.71M-28.4%
Q3 FY2025Sep 30, 2025$2.83M-84.2%
Q2 FY2025Jun 30, 2025$3.66M-83.5%
Q1 FY2025Mar 31, 2025$4.30M-79.7%
Q4 FY2024Dec 31, 2024$9.37M-60.4%
Q3 FY2024Sep 30, 2024$17.92M-34.1%
Q2 FY2024Jun 30, 2024$22.15M+2.5%
Q1 FY2024Mar 31, 2024$21.24M-0.3%
Q4 FY2023Dec 31, 2023$23.68M+55.4%
Q3 FY2023Sep 30, 2023$27.20M+60.3%
Q2 FY2023Jun 30, 2023$21.62M+46.0%
Q1 FY2023Mar 31, 2023$21.29M+47.3%
Q4 FY2022Dec 31, 2022$15.24M+20.7%
Q3 FY2022Sep 30, 2022$16.97M+58.4%
Q2 FY2022Jun 30, 2022$14.80M+23.1%
Q1 FY2022Mar 31, 2022$14.46M+94.2%
Q4 FY2021Dec 31, 2021$12.62M+143.3%
Q3 FY2021Sep 30, 2021$10.71M+83.7%
Q2 FY2021Jun 30, 2021$12.02M+617.0%
Q1 FY2021Mar 31, 2021$7.45M+1157.6%
Q4 FY2020Dec 31, 2020$5.19M+688.3%
Q3 FY2020Sep 30, 2020$5.83M+468.2%
Q2 FY2020Jun 30, 2020$1.68M–
Q1 FY2020Mar 31, 2020$592.00K–
Q4 FY2019Dec 31, 2019$658.00K–
Q3 FY2019Sep 30, 2019$1.03M–

More LeonaBio figures

See a number that looks wrong?